Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Competition is expected to ramp up next year when cheaper alternative versions of semaglutide — the active ingredient in Novo’s Wegovy — launch after semaglutide ... as effective as Lilly’s ...

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

The main result – reported earlier – was an overall weight reduction of 20.2% with Zepbound at 72 weeks, compared to 13.7% with Wegovy.

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.